0

Ongoing Medicare Privatization Will Hurt Pharma As Much As the IRA

  The pharmaceutical industry is in a frenzy over the recently released list of the drugs subject to price negotiation under the Inflation Reduction Act of 2023 (IRA) and the Act’s potential impact on profits. But an even bigger force… Continue Reading

0

The Emerging Outcomes Demonstration / Cost Management Challenge

The current healthcare environment reshapes the three key factors in market access – value, evidence, and commercial positioning of new treatments. Greater emphasis on patient centricity meets budget cuts. Leading to a sharper focus on demonstrating patient benefit value specific… Continue Reading

0

The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?

The UK has always been on the forefront of market access with its unique pathways within England, but especially also considering Wales, Ireland and Scotland as well. Furthermore, since the Brexit there were new innovation paths introduced. The core question remains, how… Continue Reading

0

MArS Supplier Spotlight

Supplier Spotlight® highlights the unique skill sets and service offerings from organizations who are part of our CONNECTED COMMUNITY™. Below is an interview with Market Access & Pricing Strategy (MArS), the German-speaking market access experts. Tell us about MArS Market Access… Continue Reading